HCPCS (medical SC)
J3590
NOC biologic + NDC
Phase 1
Identify what you're billing
Confirm benefit channel (pharmacy vs medical SC), indication, weight (for q4w vs q8w), and dosing phase.
IL-17 class comparison — Bimzelx vs IL-17A vs IL-23/TNF biologics FDA verified May 2026
Bimzelx is the only dual IL-17A/F agent. Knowing the class hierarchy is the key to step-therapy navigation.
The psoriasis biologic landscape sorts into four mechanism classes: TNF inhibitors (Humira and biosimilars, Enbrel, Remicade, Simponi Aria, Cimzia) — the legacy step; IL-17 inhibitors (Cosentyx IL-17A, Taltz IL-17A, Bimzelx IL-17A/F); IL-23 inhibitors (Skyrizi, Tremfya, plus IL-12/23 Stelara and biosimilars); and oral small molecules (Otezla, Sotyktu). Bimzelx is differentiated by neutralizing both IL-17A and IL-17F — head-to-head trials have shown the highest PASI 100 rates of any approved psoriasis biologic.
| Drug | Target | Route | Maintenance freq | Indications |
|---|---|---|---|---|
| Bimzelx (bimekizumab) | IL-17A + IL-17F (dual) | SC | q8w (PsO) / q4w (PsA/AS/HS) | PsO, PsA, AS, nr-axSpA, HS |
| Cosentyx (secukinumab) | IL-17A | SC + IV (PsA/AS/nr-axSpA) | q4w | PsO, PsA, AS, nr-axSpA, HS |
| Taltz (ixekizumab) | IL-17A | SC | q4w | PsO, PsA, AS, nr-axSpA |
| Skyrizi (risankizumab) | IL-23 (p19) | SC + IV (CD induction) | q12w (PsO) | PsO, PsA, CD, UC |
| Tremfya (guselkumab) | IL-23 (p19) | SC + IV (UC/CD induction) | q8w (PsO) | PsO, PsA, UC, CD |
| Stelara (ustekinumab) | IL-12/23 (p40) | SC + IV induction | q12w | PsO, PsA, CD, UC; biosimilars launching |
| Humira (adalimumab) + biosimilars | TNF-α | SC | q2w | PsO, PsA, AS, HS, RA, CD, UC, JIA |
Why dual IL-17A/F matters clinically: IL-17F is co-expressed with IL-17A in psoriatic plaque
and HS lesion biopsies. IL-17F binds the same receptor (IL-17RA/IL-17RC) and drives independent downstream
inflammation. IL-17A monoclonal antibodies leave IL-17F signaling intact. Neutralizing both A and F produces
higher PASI 100 rates and faster onset of complete clearance than IL-17A alone in head-to-head trials.
Payer step-therapy reality: several large commercial plans now position Bimzelx as
step-after-IL-17A rather than first-line IL-17, requiring documented failure of Cosentyx or Taltz
before approving Bimzelx for plaque psoriasis. This is a tactical step-therapy design that prefers cheaper
IL-17A agents first and reserves dual IL-17A/F for non-responders. PA submissions for Bimzelx in first-line
IL-17 positioning will frequently deny — document prior IL-17A trial or clinical rationale for skipping it.
Dosing & unit math FDA label current
Per FDA prescribing information. SC only - no IV formulation.
| Indication | Induction | Maintenance | Notes |
|---|---|---|---|
| Plaque psoriasis (adult) | 320 mg SC (2 × 160 mg) at weeks 0, 4, 8, 12, 16 | 320 mg SC every 8 weeks | Patients ≥120 kg may continue 320 mg q4w after week 16 |
| Psoriatic arthritis (adult) | 160 mg SC every 4 weeks | 160 mg q4w (no loading) | If concurrent moderate-severe plaque PsO: 320 mg q4w × 5 then q8w |
| Ankylosing spondylitis | 160 mg SC every 4 weeks | 160 mg q4w | — |
| nr-axSpA | 160 mg SC every 4 weeks | 160 mg q4w | — |
| Hidradenitis suppurativa | 320 mg SC at weeks 0, 2, 4 (induction) | 320 mg q4w; consider q2w if inadequate response | HS regimen distinct from PsO — induction every 2 weeks initially |
Plaque psoriasis: induction vs maintenance
- Induction (weeks 0–16): 320 mg q4w × 5 doses
- Maintenance (week 16+): 320 mg q8w (most patients)
- Weight-based exception: patients ≥120 kg may continue 320 mg q4w throughout maintenance per FDA label, particularly if PASI 90 not achieved
- Two injections per dose: 320 mg = two 160 mg/mL prefilled syringes or auto-injectors (administer separately at different injection sites)
Worked example — year-one plaque PsO patient (under 120 kg)
# Induction phase, weeks 0-16:
5 doses × 320 mg = 1,600 mg total
Doses administered: 5
# Maintenance phase, week 24 through week 52:
q8w cadence: weeks 24, 32, 40, 48 = 4 doses
4 doses × 320 mg = 1,280 mg
Year-1 maintenance doses: 4
# Year-1 total: 9 doses × 320 mg = 2,880 mg / year
# Year-2 steady state: 6.5 doses/yr (q8w) × 320 mg = ~2,080 mg / year
5 doses × 320 mg = 1,600 mg total
Doses administered: 5
# Maintenance phase, week 24 through week 52:
q8w cadence: weeks 24, 32, 40, 48 = 4 doses
4 doses × 320 mg = 1,280 mg
Year-1 maintenance doses: 4
# Year-1 total: 9 doses × 320 mg = 2,880 mg / year
# Year-2 steady state: 6.5 doses/yr (q8w) × 320 mg = ~2,080 mg / year
Required pre-initiation checks
- Latent TB screening (interferon-gamma release assay or PPD) before initiation, with annual repeat per payer policy
- Baseline LFTs (ALT, AST, ALP, bilirubin) — required for Bimzelx specifically due to hepatic function W&P
- No active serious infection
- For IBD patients: counsel on risk of IBD exacerbation; many payers exclude or require IL-23 alternative
- Screen for suicidal ideation / behavior (W&P)
- Live vaccine status (avoid live vaccines during therapy)
- Pregnancy considerations — clinical decision per FDA label
NDC reference FDA NDC Directory verified May 2026
UCB labeler 50474. Verify exact carton NDC against current FDA NDC Directory at billing time.
| NDC (10-digit) | NDC (11-digit) | Formulation | Use |
|---|---|---|---|
50474-700-79 |
50474-0700-79 |
160 mg / mL prefilled syringe, single | SC self-injection (160 mg dose) or 320 mg with two syringes |
50474-700-71 |
50474-0700-71 |
160 mg / mL prefilled syringe, 2-pack | SC 320 mg dose (one carton = full dose) |
50474-701-79 |
50474-0701-79 |
160 mg / mL auto-injector ("pen"), single | SC self-injection — alternate device option |
50474-701-71 |
50474-0701-71 |
160 mg / mL auto-injector, 2-pack | SC 320 mg dose via auto-injector |
11-digit NDC required on most claim forms. Pad the labeler segment to 5 digits: e.g.,
50474-0700-79. Use the
N4 qualifier in CMS-1500 Box 24A and UB-04 Box 43. Pharmacy NCPDP claims
accept either format per the payer's BIN/PCN configuration.
Verify the dose count against the NDC. Bimzelx is supplied in single-syringe and 2-pack
cartons. A 320 mg dose requires two 160 mg units; document on the medical-benefit claim that both syringes
were administered (or both auto-injectors used) — one NDC line at 320 mg or two lines at 160 mg each.
Pharmacy benefit handles this through days-supply / quantity dispensed.
Phase 2
Code the claim
Medical-benefit SC uses J3590 (NOC biologic) + 11-digit NDC + CPT 96372. Pharmacy benefit uses NCPDP D.0.
Administration codes CPT verified May 2026
Bimzelx is SC; medical-benefit administration uses 96372. Patient self-injection at home has no admin CPT.
| Code | Description | When to use |
|---|---|---|
96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | Primary admin code for in-office Bimzelx SC injection (medical benefit). Bill one unit per encounter regardless of single vs dual injection within the same session, per most payer guidance. |
96365 / 96413 |
IV infusion codes | Not applicable. Bimzelx has no IV formulation. |
| No CPT | Patient self-injection at home | No CPT code — specialty pharmacy dispenses and provides injection-teach; office not involved in claim submission beyond writing the Rx. |
96372 is rarely billed for Bimzelx. The dominant pathway is pharmacy-benefit dispensing with
the patient self-injecting at home after a one-time teach visit (which may itself bill as an E/M, not as 96372
if no drug was administered in office that day). Office administration of Bimzelx through the medical benefit
is unusual and requires payer-specific verification — some plans do not cover medical-benefit Bimzelx at all.
Injection-teach billing: for the first in-office training visit, bill the E/M code at the
appropriate level (e.g., 99213–99214) for the time spent counseling. If the office actually administers
the dose during that visit, add 96372 + J3590 + NDC for the drug.
Modifiers CMS verified May 2026
JZ — whole-syringe / whole-auto-injector use (default)
Effective July 1, 2023, CMS requires JZ on claims for single-dose container drugs when no drug is discarded — but only for codes on the CMS single-dose container list. Bimzelx is supplied as prefilled syringes and auto-injectors (single-dose devices) and is administered in fixed-dose increments (160 mg or 320 mg via two devices), so JZ is the default modifier for medical-benefit SC Bimzelx claims. There is effectively no partial-dose scenario.
JW — documented wastage (rare for Bimzelx)
Wastage is uncommon because the patient receives the whole device(s). JW is occasionally appropriate if a PFS is damaged during attempted administration and discarded; document the device, lot number, and reason in the medical record.
Modifier 25 — situational
Use modifier 25 on the E/M code when a significant, separately identifiable E/M service is performed on the same day as a 96372 injection (e.g., separate evaluation for a different complaint). Routine pre-injection screening is bundled.
340B modifiers (JG, TB)
For 340B-acquired Bimzelx (rare given pharmacy-benefit dominance), follow your MAC's 340B modifier policy. Most 340B-eligible facilities access Bimzelx through specialty distributors with 340B pricing where applicable.
ICD-10-CM diagnosis codes FY2026 verified May 2026
Use indication-specific codes. Unspecified codes (L40.9, M45.9) increase step-therapy denials.
| ICD-10 | Description | Indication |
|---|---|---|
L40.0 | Psoriasis vulgaris (plaque psoriasis) | Plaque PsO — primary code |
L40.1 / L40.2 / L40.3 / L40.4 | Other psoriasis variants (generalized pustular, palmaris et plantaris, guttate, flexural) | Off-label per FDA; payer-specific |
L40.50 | Arthropathic psoriasis, unspecified | PsA |
L40.51 | Distal interphalangeal psoriatic arthropathy | PsA |
L40.52 | Psoriatic arthritis mutilans | PsA |
L40.53 | Psoriatic spondylitis | PsA |
L40.59 | Other psoriatic arthropathy | PsA |
M45.0–M45.9 | Ankylosing spondylitis (by spinal region) | AS |
M45.A0–M45.A4 | Non-radiographic axial spondyloarthritis | nr-axSpA (FY2024+ specific codes) |
M46.80–M46.89 | Other specified inflammatory spondylopathies | nr-axSpA (alternate) |
M46.9 | Unspecified inflammatory spondylopathy | Acceptable for nr-axSpA but prefer M45.Ax |
L73.2 | Hidradenitis suppurativa | HS — primary code |
Document severity for plaque PsO. Most payers require BSA ≥10%, PASI ≥12, or DLQI ≥10
for moderate-severe plaque PsO. For AS, ASAS-defined criteria are typical. For HS, Hurley staging (II or III)
is the dominant payer threshold. Submitting Bimzelx PA without severity documentation is the #3 cause of
Bimzelx-specific denials.
Site of care & place of service Verified May 2026
Bimzelx is overwhelmingly a home-self-injection drug. Pharmacy-benefit dispensing through specialty pharmacy bypasses medical-benefit POS rules entirely — the drug ships to the patient's home. Medical-benefit in-office administration (rare) uses standard SC injection POS codes.
| Setting | POS | Claim form | Electronic |
|---|---|---|---|
| Patient home (SC, self-inject) | 12 / n/a (pharmacy benefit) | NCPDP claim from specialty pharmacy | NCPDP D.0 |
| Physician office (medical benefit SC) | 11 | CMS-1500 | 837P |
| Dermatology / rheumatology / specialty clinic | 11 | CMS-1500 | 837P |
| Hospital outpatient (rare) | 19 or 22 | UB-04 / CMS-1450 | 837I |
| Injection-teach visit | 11 | CMS-1500 (E/M only, no 96372 unless drug given) | 837P |
Pharmacy benefit is the default. If your office routinely stocks Bimzelx for medical-benefit
administration, verify with each payer that medical-benefit SC biologics are reimbursable — many plans
require specialty pharmacy as the only acceptable channel. The pharmacy-benefit pathway is also generally less
expensive for the patient (Part D OOP cap post-IRA; commercial Rx tiering) and avoids buy-and-bill cash flow risk.
Claim form field mapping Verified May 2026
CMS-1500 / 837P for medical-benefit SC. NCPDP D.0 for pharmacy benefit (dominant pathway).
Medical-benefit claim (J3590) — CMS-1500 / 837P
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | Format: N450474070079ML1 (per syringe) |
| HCPCS J3590 + admin CPT 96372 | 24D | Each on its own line. Add description "bimekizumab-bkzx 160 mg" in NTE. |
| Drug units (mg) | 24G | Administered mg (160 or 320). NOC codes often require mg in remarks. |
| Drug description | NTE / Box 19 | Critical for J3590 — "Bimzelx (bimekizumab-bkzx) 160 mg/mL SC, NDC 50474-0700-79" |
| ICD-10 | 21 | L40.0 (PsO), L40.5x (PsA), M45.x / M45.Ax (AS / nr-axSpA), L73.2 (HS) |
| PA number | 23 | Required by virtually all payers |
| Billed charge | 24F | Provider acquisition + appropriate margin; NOC reimbursement is at payer discretion |
Pharmacy benefit dispensing — NCPDP D.0 (dominant pathway)
Bimzelx is dispensed by a specialty pharmacy and adjudicated through the pharmacy benefit (Part D for Medicare; commercial Rx benefit otherwise). The specialty pharmacy submits an NCPDP claim with the NDC, days supply, and DAW code. The prescribing provider's office writes the Rx and supports the PA but does not submit claims for SC Bimzelx in this pathway.
J3590 NOC claims require manual review. Unclassified codes do not autoadjudicate. Expect 15-30
day review windows, manual pricing, and frequent requests for itemized invoice and NDC verification. Pharmacy
benefit is faster and more predictable for Bimzelx — route accordingly when possible.
Form references: NUCC (CMS-1500) · NCPDP (D.0 pharmacy).
Phase 3
Get paid
Universal PA. TB + LFT screening required. Step therapy from TNFi (PsA/AS/HS) or IL-17A (PsO) common.
Payer policy snapshot Reviewed May 2026
Universal prior auth. TB screening + LFT monitoring required everywhere. Step therapy varies by indication.
| Payer | PA? | Step therapy | Benefit channel | Re-auth |
|---|---|---|---|---|
| UnitedHealthcare Bimekizumab medical/pharmacy policy |
Yes | PsO: prefer adalimumab biosimilar + IL-17A trial. PsA/AS: TNFi step. HS: adalimumab/biosimilar. | Pharmacy benefit preferred; medical SC limited | 12 mo w/ documented PASI/severity response + LFTs current |
| Aetna CPB 0658 (biologics for inflammatory disease) |
Yes | TNFi failure required for PsA/AS. PsO: TNFi + IL-17A failure typical. HS: adalimumab trial. | Specialty Rx only | w/ documented response + LFTs within 12 mo |
| Anthem / Carelon Inflammatory disease biologics policy |
Yes | TNFi step (PsA/AS/HS). PsO: variable; some plans require IL-17A trial first. | Specialty Rx | w/ disease stability + LFT monitoring |
| Cigna / Express Scripts Bimzelx coverage policy |
Yes | TNFi step for PsA/AS/HS; PsO requires step through preferred biologic (often Humira biosimilar + Cosentyx/Taltz) | Accredo specialty Rx | 12 mo |
| BCBS FEP 5.21.07 (interleukin inhibitors) |
Yes | TNFi step for PsA/AS; PsO some plans first-line IL-17 allowed | Specialty Rx | w/ documented response |
Key finding — IL-17A step before IL-17A/F: several large commercial plans now position
Bimzelx specifically as a step-after-IL-17A drug for plaque psoriasis. The rationale is cost-stewardship:
Cosentyx and Taltz are similarly priced and clinically effective for the majority of patients, so payers
reserve Bimzelx for non-responders or those who specifically want dual IL-17A/F coverage. Practices should
front-load IL-17A failure documentation in the initial PA submission to avoid step-therapy denials.
LFT monitoring is a payer requirement, not just a clinical recommendation. Several large
commercial PAs require baseline LFTs within 30 days of initiation and periodic LFTs (typically at weeks 8, 16,
and every 8–12 weeks thereafter). Missing or stale LFTs in the chart is the #2 cause of Bimzelx PA denial
after TB screening gaps.
What to document for approval
- Confirmed diagnosis with ICD-10 specific to indication (L40.0, L40.5x, M45.x, M45.Ax, L73.2)
- Severity: BSA / PASI / DLQI for PsO; ASAS criteria for AS; Hurley II/III for HS
- For PsA/AS/HS: prior TNFi trial(s) with dates, doses, duration, reason for discontinuation
- For PsO (per payer): prior IL-17A trial (Cosentyx or Taltz) with dates, doses, response/failure documentation
- TB screening (IGRA or PPD) within 12 months — mandatory per FDA W&P + payer policy
- Baseline LFTs within 30–90 days of initiation — specific to Bimzelx
- For IBD patients: documented clinical justification (IL-17 risk vs benefit) or alternative IL-23 considered
- No active serious infection
- Suicidal ideation screening (W&P) — some payers require documentation
Medicare reimbursement No permanent J-code Q2 2026
Bimzelx is overwhelmingly Part D (pharmacy benefit). Medical-benefit Part B uses J3590 NOC.
Q2 2026 payment snapshot — Bimzelx
Effective April 1 – June 30, 2026 · No permanent J-code; NOC J3590 priced by MAC contractor at invoice
Medical benefit (Part B)
J3590 NOC
MAC pricing per invoice; manual review
Pharmacy benefit (Part D)
NDC + WAC
Year-1 PsO WAC ~$60-70K
Part D OOP cap (2026)
$2,000
Annual patient OOP cap (IRA)
Annualized cost — plaque PsO under 120 kg: 9 doses year-1 (5 induction + 4 q8w maintenance)
× 320 mg = 2,880 mg. WAC reported in the ~$60K–$70K range for year-1; year-2 steady state ~$45K–$55K.
For PsA/AS at 160 mg q4w: 13 doses/yr × 160 mg = 2,080 mg/yr, similar annualized WAC. HS at 320 mg q4w
runs higher. Net price after rebates and copay support is materially lower and PBM-contract specific.
Part B vs Part D
Bimzelx is a self-administered SC drug, so for Medicare beneficiaries it is overwhelmingly paid under Part D (the prescription drug benefit). Part B applies only in the rare case of in-office administration where the drug is provider-acquired and billed under the medical benefit using J3590 NOC. The patient's out-of-pocket exposure under Part D is capped at $2,000 annually post-IRA (2025+); under Part B, 20% coinsurance with no cap unless secondary coverage applies.
Coverage
No NCD specific to bimekizumab. MAC coverage under J3590 follows general unclassified-biologic rules: invoice-based pricing, manual review, indication-specific medical necessity. Part D plan formularies increasingly include Bimzelx at a specialty tier (typically tier 5) with PA and step-therapy restrictions aligned with commercial payer policy.
Code history
- October 17, 2023 — FDA approval (plaque psoriasis, initial US approval)
- September 23, 2024 — PsA, AS, nr-axSpA indications added simultaneously (BE OPTIMAL / BE COMPLETE / BE MOBILE 1 & 2)
- November 25, 2024 — moderate-to-severe HS indication added (BE HEARD I & II)
- Q2 2026 — no permanent HCPCS J-code; medical-benefit claims continue to use
J3590NOC with NDC documentation - Watch for HCPCS quarterly updates — a permanent bimekizumab J-code is anticipated as utilization grows but has not been assigned as of Q2 2026
Patient assistance — Bimzelx Navigate (UCBcares) UCB verified May 2026
- Bimzelx Navigate / UCBcares: 1-844-599-2273 (UCB-CARES) — central support hub for benefits investigation, PA, copay, and patient education
- Bimzelx Copay Card (commercial patients only): as low as $0 copay; annual benefit caps apply (varies by program year — verify current limits with UCBcares). Excludes Medicare, Medicaid, TRICARE, VA, CHIP, and other federal program patients.
- Bimzelx Free Trial / Bridge Program: starter supply available for new starts pending coverage determination (eligibility criteria apply)
- UCB Patient Assistance Program (UCB PAP): free product for uninsured / government-insured patients meeting income limits (typically ≤500% FPL)
- Foundation backup: Patient Advocate Foundation Copay Relief Program, Patient Access Network (PAN) Foundation, and HealthWell Foundation — disease-specific funds may cover psoriasis, PsA, AS, or HS copay for federally-insured patients when open
- Web: bimzelx.com · bimzelxhcp.com
Need to model what a specific patient will actually pay after copay assistance, deductible, coinsurance,
and OOP max? Run a CareCost Estimate — Bimzelx pharmacy benefit
pre-loaded.
Copay card excludes federal program patients. Medicare, Medicaid, TRICARE, VA, CHIP, and other
government-insured patients are not eligible for the Bimzelx copay card. For these patients, route to UCB PAP
(income-based free drug) or independent disease-specific foundations (PAN, HealthWell, Patient Advocate
Foundation) for copay assistance.
Phase 4
Fix problems
TB screening gaps, LFT documentation, step-therapy, and pharmacy-vs-medical routing are the top denials.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| #1 — TB screening not documented | PA submitted without latent TB test result (IGRA or PPD) — mandatory per FDA W&P | Submit TB test (interferon-gamma release assay or PPD) within 12 months. If positive, submit treatment plan for latent TB infection. |
| #2 — Step therapy not satisfied | PsA/AS PA without TNFi failure; or PsO PA without IL-17A trial (Cosentyx/Taltz) where required | Submit prior treatment history with dates, doses, duration, reason for failure. For HS: document Humira/adalimumab biosimilar trial. For PsO at IL-17A-step plans: document Cosentyx/Taltz failure or contraindication. |
| #3 — Severity documentation missing | Plaque PsO PA without BSA/PASI/DLQI; AS without ASAS criteria; HS without Hurley staging | Add BSA ≥10% / PASI ≥12 / DLQI ≥10 for PsO. ASAS-defined criteria + MRI/x-ray for AS/nr-axSpA. Hurley II or III for HS. Quote specific numbers in the PA narrative. |
| #4 — Pharmacy vs medical benefit routing error | Medical-benefit claim submitted when payer requires specialty Rx, or vice versa | Verify benefit channel with the payer. Most plans route Bimzelx through specialty pharmacy only. Reroute via Bimzelx Navigate / UCBcares benefit investigation. |
| LFT monitoring not documented | Baseline or follow-up LFTs missing — specific to Bimzelx W&P | Submit baseline ALT/AST/ALP/bilirubin within 30–90 days. For continuation, include LFTs at weeks 8, 16, and ongoing 8–12-week intervals. |
| J3590 priced at $0 (NOC unclassified) | Manual NOC review pending or insufficient documentation | Submit itemized invoice, 11-digit NDC, drug description in NTE (e.g., "Bimzelx bimekizumab-bkzx 160 mg/mL"), and PA approval letter. Most MACs will manually price after documentation. |
| NDC format / mismatch | 10-digit submitted when payer requires 11-digit; or wrong NDC for dose | Use 11-digit padded NDC (e.g., 50474-0700-79). For 320 mg dose, document both 160 mg units administered. |
| IBD exacerbation flag | Patient with concurrent IBD (Crohn's, UC) flagged for caution | Document IBD status, prior flare history, and clinical justification for IL-17 use despite IBD risk. Some plans require IL-23 alternative (Skyrizi, Tremfya) for patients with comorbid IBD. |
| Concurrent indication ambiguity | Patient with both PsO and PsA — unclear which dosing regimen applies | Document the dominant clinical driver. Per FDA label, concurrent moderate-severe plaque PsO + PsA uses the 320 mg q4w × 5 then q8w regimen (PsO-driven). |
| Suicidal ideation screening missing | W&P item not addressed in PA narrative | Add a brief statement: "Patient screened, no current SI/SH; will monitor at each visit." Some payers require this. |
| Pediatric denial | Bimzelx requested for patient <18 years old | Bimzelx is approved for adults only as of Q2 2026. Pediatric psoriasis: Cosentyx (≥6 yr) or Stelara are FDA-approved alternatives. |
Frequently asked questions
What is the HCPCS code for Bimzelx?
Bimzelx (bimekizumab-bkzx) has no permanent J-code as of Q2 2026. Medical-benefit claims for
in-office subcutaneous administration use HCPCS J3590 (unclassified biologic) paired with the
11-digit NDC, the administered mg, and patient-specific dose documentation in the NTE segment. Most utilization,
however, runs through the pharmacy benefit (specialty Rx) because patients self-inject at home; pharmacy claims
use the NDC under NCPDP D.0 and do not require a J-code.
Bimzelx vs Cosentyx — what's IL-17A/F vs IL-17A?
Bimzelx (bimekizumab) is a dual IL-17A and IL-17F inhibitor — it neutralizes both cytokines. Cosentyx (secukinumab) and Taltz (ixekizumab) inhibit IL-17A only. IL-17F is co-expressed with IL-17A in psoriatic and HS lesions and contributes independently to inflammation; dual blockade has produced higher PASI 100 (complete clearance) rates than IL-17A monotherapy in head-to-head psoriasis trials. Bimzelx also carries explicit FDA labeling for hepatic function abnormalities and oral candidiasis at a higher rate than IL-17A-only agents — require baseline LFTs.
Step therapy from Cosentyx or Taltz to Bimzelx?
Yes, increasingly. Several large commercial plans (UnitedHealthcare, Cigna/Express Scripts, some BCBS plans) now position Bimzelx as step-after-IL-17A for plaque psoriasis — meaning the patient must have trialed Cosentyx or Taltz first. The rationale is cost stewardship: IL-17A agents are similarly priced and clinically effective for most patients, so payers reserve Bimzelx for non-responders. Submit the IL-17A trial history (dates, doses, PASI response or lack thereof) in the initial PA.
Pharmacy vs medical benefit for SC self-admin?
Pharmacy benefit is dominant. Bimzelx is a self-administered SC biologic dispensed by specialty pharmacy and adjudicated through Part D / commercial Rx under NCPDP D.0. The medical benefit applies only when an office or HOPD administers the dose — typically for an injection-teach visit or for patients who cannot self-inject. Medical-benefit claims use J3590 + NDC + CPT 96372. Many plans do not cover medical-benefit Bimzelx at all and require specialty pharmacy.
Psoriasis loading vs maintenance dosing?
Plaque psoriasis: 320 mg SC (two 160 mg injections) at weeks 0, 4, 8, 12, and 16 (5 induction doses), then 320 mg SC every 8 weeks. Patients weighing ≥120 kg may continue 320 mg q4w after week 16, particularly if PASI 90 is not achieved. PsA / AS / nr-axSpA: 160 mg SC every 4 weeks (no induction loading). HS: 320 mg at weeks 0, 2, 4 (induction), then 320 mg q4w (may up-titrate to q2w if response inadequate).
HS indication coverage?
Bimzelx was FDA-approved for hidradenitis suppurativa on November 25, 2024. The HS regimen is distinct from plaque PsO: induction at weeks 0, 2, 4 (every 2 weeks), then 320 mg q4w maintenance. Payer step therapy for HS overwhelmingly requires prior Humira (adalimumab) or biosimilar trial — Humira was the first FDA-approved biologic for HS, so it sits at the top of every HS step-therapy ladder. Document Hurley staging (II or III) and prior adalimumab failure.
TB screening requirements?
Mandatory before initiation per FDA Warnings & Precautions. Use an interferon-gamma release assay (IGRA like QuantiFERON-TB Gold or T-SPOT.TB) or tuberculin skin test (PPD). Results must be within 12 months for most payer PAs. If positive (latent TB), the patient must be on or have completed latent TB infection treatment before starting Bimzelx. TB screening gaps are the #1 cause of Bimzelx PA denial.
Boxed warning — hepatic monitoring?
Bimzelx does not have a boxed warning. However, the FDA Warnings & Precautions section flags hepatic function abnormalities — elevated transaminases (ALT/AST > 3× ULN) were reported in clinical trials at a higher rate than IL-17A-only agents. Baseline LFTs (ALT, AST, ALP, bilirubin) are required before initiation, with periodic monitoring (typically weeks 8, 16, then every 8–12 weeks). LFT documentation is now a standard payer PA requirement specific to Bimzelx.
What is the annual WAC cost of Bimzelx?
Approximately $60,000–$70,000 WAC per year for the year-one plaque PsO regimen (induction through week 16 + q8w maintenance). PsA/AS/nr-axSpA at 160 mg q4w runs in a similar annualized band. HS at 320 mg q4w (or q2w if up-titrated) runs higher. Net price after PBM rebates, manufacturer copay assistance, and specialty-pharmacy discounts is materially lower and varies by plan. Bimzelx is in the same WAC band as Cosentyx and Taltz for the comparable plaque PsO regimen.
How does Bimzelx compare to IL-23 biologics like Skyrizi and Tremfya?
IL-17 inhibitors (Bimzelx IL-17A/F, Cosentyx IL-17A, Taltz IL-17A) block the downstream effector cytokine and tend to produce faster onset and higher PASI 100 rates. IL-23 inhibitors (Skyrizi p19, Tremfya p19, Stelara p40) block the upstream driver of Th17 differentiation and offer less frequent dosing (q12w for Skyrizi maintenance). IL-23 agents are often preferred when concurrent IBD is present because IL-17 inhibitors can exacerbate IBD. Bimzelx's dual IL-17A/F mechanism currently has the highest reported PASI 100 rates among approved psoriasis biologics in head-to-head trials.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- FDA — BIMZELX (bimekizumab-bkzx) Prescribing Information
- DailyMed — BIMZELX label search
- Bimzelx.com — patient site
- Bimzelx HCP — provider site
- CMS — Medicare Part B Drug ASP Pricing File
- CMS — HCPCS quarterly update file
- CMS — JW Modifier and JZ Modifier policy
- UCB — FDA approvals for Bimzelx in PsA, nr-axSpA, AS (Sep 23, 2024)
- FDA — Bimzelx HS approval (Nov 25, 2024)
- Aetna Clinical Policy Bulletin 0658 — Biologics for Inflammatory Disease
- UnitedHealthcare — Provider portal (medical & pharmacy policies)
- Cigna / Express Scripts — Coverage policies
- FDA National Drug Code Directory
- UCB, Inc. — manufacturer
About this page
We maintain this page as a living reference. Medicare ASP pricing references are bound to our underlying CareCost data layer and refresh automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| HCPCS J-code assignment (NOC J3590) | Quarterly | Watch CMS HCPCS quarterly updates for permanent bimekizumab J-code |
| Payer policies (UHC, Aetna, Cigna, Anthem, BCBS) | Semi-annual | Manual review against published payer policy documents |
| HCPCS / CPT / modifier rules | Quarterly | JZ/JW applicability and admin-code conventions |
| NDC, dosing, FDA label | Event-driven | Tied to manufacturer document version + FDA label revision date |
| Pharmacy-benefit pricing (WAC / net) | Annual | WAC changes reviewed annually; PBM net pricing varies and is not published |
| Class comparison (IL-17, IL-23, TNF) | Semi-annual | Updated as competing biologics gain new indications or biosimilars launch |
Reviewer
SME audit completed May 22, 2026. Verified against current FDA prescribing information
(DailyMed BLA 761151) and UCB press releases. Key audit corrections: HS approval date corrected from Jul 22, 2024 to Nov 25, 2024; PsA/AS/nr-axSpA approval corrected from Sep 24 to Sep 23, 2024; pivotal trial program names added (BE READY/BE VIVID/BE SURE for PsO; BE OPTIMAL/BE COMPLETE for PsA; BE MOBILE 1 & 2 for axSpA; BE HEARD I & II for HS). Confirmed: no FDA boxed warning — suicidal ideation, hepatic function abnormalities, infections, TB, IBD, oral candidiasis are W&P only.
Change log
- — SME audit pass. Corrected HS approval date (Nov 25, 2024 vs Jul 22, 2024 previously cited); corrected PsA/AS/nr-axSpA approval (Sep 23 vs Sep 24); added pivotal trial program names. Confirmed no boxed warning (W&P only) and that the dual IL-17A/F mechanism characterization is current and correct.
- — Initial publication. No permanent J-code; medical-benefit SC uses J3590 NOC. Dual IL-17A/F mechanism documented. Class comparison vs Cosentyx, Taltz, Skyrizi, Tremfya, Stelara, Humira included. Payer policies: UHC, Aetna CPB 0658, Cigna/Express Scripts, Anthem/Carelon, BCBS FEP 5.21.07. TB screening + LFT monitoring required.
Methodology
Every claim on this page is sourced inline. Coding guidance reflects current CMS HCPCS conventions and the fact that bimekizumab has no permanent J-code as of Q2 2026. Payer policies are read directly from each payer's published medical/pharmacy policy documents. We do not paraphrase from billing-software vendor blogs. The dual IL-17A/F mechanism distinction is the key clinical and step-therapy lever for this drug and is made explicit in multiple sections rather than buried in a footnote.